- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- IgAN
- Events
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefR
- Radiology Toolkit
- On Demand Webinars
- Infographics
- Podcasts
- Videos
- Request a Presentation
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Overview Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NephU Community Advisors, Dr Neera Dahl, Dr Arlene Chapman, and Dr Frederic F. Rahbari Oskoui present an overview of autosomal dominant polycystic kidney disease (ADPKD) and answer common questions health care professionals have about ADPKD.
Drs Neera Dahl, Arlene Chapman, and Frederic F. Rahbari Oskoui are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).
If you would like to register for the 3:00 pm to 4:00 pm EDT broadcast or 9:00 pm to 10:00 pm EDT broadcast, please click below:
Featured Speakers
Neera Dahl, MD, PhD
Professor of Medicine (Nephrology), Medical Director of Nephrology and Director of the Nephrology Clinical Trials ProgramYale School of Medicine*
Neera Dahl, MD, PhD is currently a clinician-educator and a Professor of Medicine at Yale University, School of Medicine, Section of Nephrology. She received her MD and PhD from Tufts University School of Medicine and completed her residency and fellowship at the Beth Israel Deaconess Medical Center, in Boston, MA. She has been instrumental in developing the Yale Inherited Kidney Disease Clinical Program and is the principal investigator for several ongoing clinical trials in ADPKD. She maintains an active ADPKD registry and is involved in research exploring the role of inflammation and fibrosis in the progression of ADPKD. She is also the director of the Yale Nephrology Clinical Trials Program and a member of the Scientific Advisory Board for the Polycystic Kidney Disease Foundation.
Arlene Chapman, MD
Chief Department of Medicine, Nephrology, Professor of Medicine, Nephrology-
University of Chicago*
Dr Chapman is the section Chief of Nephrology at the University of Chicago and the Director of the Clinical Research Center for the University of Chicago’s Institute for Translational Medicine.
Dr Chapman attended medical school at MacMaster School of Medicine in Ontario, Canada, followed by training in Internal Medicine at Georgetown University School of Medicine in Washington, DC and a fellowship in Renal Medicine at the University of Colorado School of Medicine. She joined the University of Colorado faculty as an Assistant Professor and was later promoted to Associate Professor. She then joined the faculty at Emory University, where she was promoted to Professor of Medicine and later accepted the role of section chief of Nephrology at the University of Chicago.
Dr Chapman’s research focuses on mechanisms of cyst formation in autosomal dominant polycystic kidney disease. She has been integrally involved in the development of novel imaging biomarkers for this disease. In addition, her career has focused on other rare conditions including ARPKD, the CAKUT disorders, ciliopathies, tuberous sclerosis complex and von Hippel Lindau disease.
Her academic contributions include membership on several NIH committees as well as the Scientific Advisory Council for the Polycystic Kidney Disease Research Foundation and the Council for the American Kidney Societies. She has also served on the editorial boards for JASN, CJASN, AJKD, Kidney International, and NDT.Frederic F Rahbari Oskoui, MD
Professor of Medicine, Nephrology-
Emory University School of Medicine*
Dr Frederic Rahbari is the director of Cystic Kidney Diseases Clinic at Emory University and has been a nephrologist practicing at Emory University Hospital in Atlanta, GA since 2006. Dr Rahbari attended medical school at Université de Bordeaux in France and completed a residency program at the same institution. After moving to the United States, Dr Rahbari did clinical and translational research on oxidative stress at New York Medical College and subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons. He has also completed a fellowship in nephrology at Emory University. Dr Rahbari has been a principal investigator in several PKD trials and is a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation.
Location
Online
Related Events
-
Cooking Demo: Dietary Considerations for Patients with IgA Nephropathy
January 8, 2025 from 12:00 pm to 1:00 pm
Join Today for Instant Access to all NephU Offerings.
Membership is free!
Join NephU today at no cost to register for this event and access to other premium content.
- The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
- Quickly learn more about the topics that interest you.
- Access our library of on-demand kidney health resources
- Gain key insights from industry experts & though leaders.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.